Biomolecular drug delivery engineers create innovative systems that transport delicate biomolecules—such as proteins, peptides, and nucleic acids—to targeted tissues or cells efficiently and safely. These biomolecules often face significant challenges, including instability, enzymatic degradation, and poor cellular uptake, which can hinder their therapeutic effectiveness. To overcome these obstacles, these engineers design and optimize delivery platforms like nanoparticles, liposomes, and polymeric carriers that protect the biomolecules, control their release, and enhance targeting capabilities. Their work is vital in advancing treatments for complex diseases such as cancer, genetic disorders, and autoimmune conditions, where precision and efficacy are critical.
Biomolecular drug delivery engineers perform extensive evaluations to ensure biocompatibility, optimize pharmacokinetics, and minimize side effects. They collaborate closely with molecular biologists, pharmacologists, and clinicians to translate laboratory discoveries into effective clinical therapies. As personalized medicine and biotechnology continue to grow, these engineers play a pivotal role in tailoring therapies to individual patient needs and overcoming biological barriers. Their ongoing innovations are essential to expanding the therapeutic potential of biomolecules and improving patient outcomes. Through integrating engineering principles with biological insights, they develop solutions that are both scientifically advanced and clinically practical. Ultimately, biomolecular drug delivery engineers help bridge the gap between scientific research and practical medicine, driving forward the future of precision therapeutics.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia